NCT03720119View on ClinicalTrials.gov

Multicentre Observational Study on the Wound Pain Relief Properties of ORTODERMINA®

CompletedOBSERVATIONAL
Enrollment

78

Participants

Timeline

Start Date

January 27, 2015

Primary Completion Date

March 5, 2018

Study Completion Date

March 5, 2018

Conditions
Wound Healing Disorder
Interventions
DRUG

Lidocaine Hydrochloride

As per clinical practice, a local treatment with ORTODERMINA® over a 14-day period (once a day) was prescribed. ORTODERMINA® contains 5% of lidocaine hydrochloride.

Trial Locations (2)

Unknown

Azienda Ospedaliero Pisana, Pisa

Ospedali Riuniti Trieste, Trieste

All Listed Sponsors
lead

SOFAR S.p.A.

INDUSTRY

NCT03720119 - Multicentre Observational Study on the Wound Pain Relief Properties of ORTODERMINA® | Biotech Hunter | Biotech Hunter